Parkinson’s Disease – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Parkinson's Disease – Pipeline Review, H1 2017’, provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease

The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects

The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

4P Therapeutics LLC

AbbVie Inc

AC Immune SA

Acorda Therapeutics Inc

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Advinus Therapeutics Ltd

Aeolus Pharmaceuticals Inc

AFFiRiS AG

Amabiotics SAS

Amarantus Bioscience Holdings Inc

American Gene Technologies International Inc

Anavex Life Sciences Corp

Angita BV

Antoxis Ltd

Aoxing Pharmaceutical Company Inc

APeT Holding BV

ApoPharma Inc

Aposense Ltd

Araclon Biotech SL

ArmaGen Inc

Arrien Pharmaceuticals LLC

Asceneuron SA

AstraZeneca Plc

Berg LLC

Bial – Portela & Ca SA

Bio-Modeling Systems SAS

BioArctic AB

Biogen Inc

BioHealthonomics Inc

Biopharm GmbH

BrainStorm Cell Therapeutics Inc

Cantabio Pharmaceuticals Inc

Cardax Inc

Carna Biosciences Inc

Cell Cure Neurosciences Ltd

CHA Bio & Diostech Co Ltd

Chipscreen Biosciences Ltd

Clera Inc

Clevexel Pharma SAS

ContraVir Pharmaceuticals Inc

Corium International Inc

Curemark LLC

Daewoong Pharmaceutical Co Ltd

Denali Therapeutics Inc

Easywell Biomedical Inc

Edison Pharmaceuticals Inc

Eli Lilly and Company

Ensemble Therapeutics Corp

Evotec AG

Fabre-Kramer Pharmaceuticals Inc

Forma Therapeutics Inc

FPRT Bio Inc

Genecode AS

Generon (Shanghai) Corp Ltd

Genervon Biopharmaceuticals LLC

GenKyoTex SA

Genmab A/S

Genzyme Corp

H. Lundbeck A/S

Heptares Therapeutics Ltd

Herantis Pharma Plc

Hisamitsu Pharmaceutical Co Inc

HitGen LTD

Huons Co Ltd

ICB International Inc

Immungenetics AG

Impel NeuroPharma Inc

InnoMedica Holding AG

Intec Pharma ltd

InterMed Discovery GmbH

International Stem Cell Corp

Io Therapeutics Inc

Jeil Pharmaceutical Co Ltd

Kainos Medicine Inc

Khondrion BV

KineMed Inc

Kissei Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Living Cell Technologies Ltd

Longevity Biotech Inc

Luye Pharma Group Ltd

M et P Pharma AG

M's Science Corp

M3 Biotechnology Inc

MedGenesis Therapeutix Inc

MedImmune LLC

Merck & Co Inc

Metabolic Solutions Development Company LLC

Minerva Neurosciences Inc

Mission Therapeutics Ltd

Mitochon Pharmaceuticals Inc

Montisera Ltd

Motac Neuroscience Ltd

Neonc Technologies Inc

Netherlands Translational Research Center BV

Neuralstem Inc

Neuraltus Pharmaceuticals Inc

Neuren Pharmaceuticals Ltd

NeuroDerm Ltd

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

New World Laboratories Inc

Newron Pharmaceuticals SpA

nLife Therapeutics SL

Novartis AG

Novo Nordisk A/S

NsGene A/S (Inactive)

Omeros Corp

Oncodesign SA

Ono Pharmaceutical Co Ltd

OPKO Health Inc

Origenis GmbH

Orion Oyj

Oryzon Genomics SA

Oxford BioMedica Plc

ParkCell AB

Parkure Ltd

Peptron Inc

Pfizer Inc

Pharma Two B Ltd

Pharmaxis Ltd

Pharmicell Co Ltd

Pharnext SA

Phenomenome Discoveries Inc

Plex Pharmaceuticals Inc

Prana Biotechnology Ltd

Prexton Therapeutics SA

Promentis Pharmaceuticals Inc

Promius Pharma LLC

Proteostasis Therapeutics Inc

Prothena Corp Plc

reMYND NV

Sage Therapeutics Inc

SanBio Inc

Saneron CCEL Therapeutics Inc

Saniona AB

Serina Therapeutics Inc

Shire Plc

Sigma-Tau SpA

SignPath Pharma Inc

Signum Biosciences Inc

SK Biopharmaceuticals Co Ltd

STATegics Inc

Stealth BioTherapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunovion Pharmaceuticals Inc

Synthonics Inc

Takara Bio Inc

TauRx Therapeutics Ltd

TechnoPhage SA

Teikoku Pharma USA Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

Trevena Inc

UCB SA

UniQure NV

Varinel Inc

VistaGen Therapeutics Inc

VivaCell Biotechnology Espana SL

Voyager Therapeutics Inc

vTv Therapeutics Inc

Wellstat Therapeutics Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Parkinson’s Disease - Overview 9

Parkinson’s Disease - Therapeutics Development 10

Parkinson’s Disease - Therapeutics Assessment 50

Parkinson’s Disease - Companies Involved in Therapeutics Development 70

Parkinson’s Disease - Drug Profiles 154

Parkinson’s Disease - Dormant Projects 737

Parkinson’s Disease - Discontinued Products 751

Parkinson’s Disease - Product Development Milestones 753

Appendix 765

List of Tables

List of Tables

Number of Products under Development for Parkinson’s Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Parkinson’s Disease – Pipeline by 2-BBB Medicines BV, H1 2017

Parkinson’s Disease – Pipeline by 4P Therapeutics LLC, H1 2017

Parkinson’s Disease – Pipeline by AbbVie Inc, H1 2017

Parkinson’s Disease – Pipeline by AC Immune SA, H1 2017

Parkinson’s Disease – Pipeline by Acorda Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Adamas Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Addex Therapeutics Ltd, H1 2017

Parkinson’s Disease – Pipeline by Advinus Therapeutics Ltd, H1 2017

Parkinson’s Disease – Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by AFFiRiS AG, H1 2017

Parkinson’s Disease – Pipeline by Amabiotics SAS, H1 2017

Parkinson’s Disease – Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Parkinson’s Disease – Pipeline by American Gene Technologies International Inc, H1 2017

Parkinson’s Disease – Pipeline by Anavex Life Sciences Corp, H1 2017

Parkinson’s Disease – Pipeline by Angita BV, H1 2017

Parkinson’s Disease – Pipeline by Antoxis Ltd, H1 2017

Parkinson’s Disease – Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017

Parkinson’s Disease – Pipeline by APeT Holding BV, H1 2017

Parkinson’s Disease – Pipeline by ApoPharma Inc, H1 2017

Parkinson’s Disease – Pipeline by Aposense Ltd, H1 2017

Parkinson’s Disease – Pipeline by Araclon Biotech SL, H1 2017

Parkinson’s Disease – Pipeline by ArmaGen Inc, H1 2017

Parkinson’s Disease – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Parkinson’s Disease – Pipeline by Asceneuron SA, H1 2017

Parkinson’s Disease – Pipeline by AstraZeneca Plc, H1 2017

Parkinson’s Disease – Pipeline by Berg LLC, H1 2017

Parkinson’s Disease – Pipeline by Bial – Portela & Ca SA, H1 2017

Parkinson’s Disease – Pipeline by Bio-Modeling Systems SAS, H1 2017

Parkinson’s Disease – Pipeline by BioArctic AB, H1 2017

Parkinson’s Disease – Pipeline by Biogen Inc, H1 2017

Parkinson’s Disease – Pipeline by BioHealthonomics Inc, H1 2017

Parkinson’s Disease – Pipeline by Biopharm GmbH, H1 2017

Parkinson’s Disease – Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Cantabio Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Cardax Inc, H1 2017

Parkinson’s Disease – Pipeline by Carna Biosciences Inc, H1 2017

Parkinson’s Disease – Pipeline by Cell Cure Neurosciences Ltd, H1 2017

Parkinson’s Disease – Pipeline by CHA Bio & Diostech Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Parkinson’s Disease – Pipeline by Clera Inc, H1 2017

Parkinson’s Disease – Pipeline by Clevexel Pharma SAS, H1 2017

Parkinson’s Disease – Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Corium International Inc, H1 2017

Parkinson’s Disease – Pipeline by Curemark LLC, H1 2017

Parkinson’s Disease – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Denali Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Easywell Biomedical Inc , H1 2017

Parkinson’s Disease – Pipeline by Edison Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Eli Lilly and Company, H1 2017

Parkinson’s Disease – Pipeline by Ensemble Therapeutics Corp, H1 2017

Parkinson’s Disease – Pipeline by Evotec AG, H1 2017

Parkinson’s Disease – Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Forma Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by FPRT Bio Inc, H1 2017

Parkinson’s Disease – Pipeline by Genecode AS, H1 2017

Parkinson’s Disease – Pipeline by Generon (Shanghai) Corp Ltd, H1 2017

Parkinson’s Disease – Pipeline by Genervon Biopharmaceuticals LLC, H1 2017

Parkinson’s Disease – Pipeline by GenKyoTex SA, H1 2017

Parkinson’s Disease – Pipeline by Genmab A/S, H1 2017

Parkinson’s Disease – Pipeline by Genzyme Corp, H1 2017

Parkinson’s Disease – Pipeline by H. Lundbeck A/S, H1 2017

Parkinson’s Disease – Pipeline by Heptares Therapeutics Ltd, H1 2017

Parkinson’s Disease – Pipeline by Herantis Pharma Plc, H1 2017

Parkinson’s Disease – Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2017

Parkinson’s Disease – Pipeline by HitGen LTD, H1 2017

Parkinson’s Disease – Pipeline by Huons Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by ICB International Inc, H1 2017

Parkinson’s Disease – Pipeline by Immungenetics AG, H1 2017

Parkinson’s Disease – Pipeline by Impel NeuroPharma Inc, H1 2017

Parkinson’s Disease – Pipeline by InnoMedica Holding AG, H1 2017

Parkinson’s Disease – Pipeline by Intec Pharma ltd, H1 2017

Parkinson’s Disease – Pipeline by InterMed Discovery GmbH, H1 2017

Parkinson’s Disease – Pipeline by International Stem Cell Corp, H1 2017

Parkinson’s Disease – Pipeline by Io Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Kainos Medicine Inc, H1 2017

Parkinson’s Disease – Pipeline by Khondrion BV, H1 2017

Parkinson’s Disease – Pipeline by KineMed Inc, H1 2017

Parkinson’s Disease – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Lead Discovery Center GmbH, H1 2017

Parkinson’s Disease – Pipeline by Living Cell Technologies Ltd, H1 2017

Parkinson’s Disease – Pipeline by Longevity Biotech Inc, H1 2017

Parkinson’s Disease – Pipeline by Luye Pharma Group Ltd, H1 2017

Parkinson’s Disease – Pipeline by M et P Pharma AG, H1 2017

Parkinson’s Disease – Pipeline by M's Science Corp, H1 2017

Parkinson’s Disease – Pipeline by M3 Biotechnology Inc, H1 2017

Parkinson’s Disease – Pipeline by MedGenesis Therapeutix Inc, H1 2017

Parkinson’s Disease – Pipeline by MedImmune LLC, H1 2017

Parkinson’s Disease – Pipeline by Merck & Co Inc, H1 2017

Parkinson’s Disease – Pipeline by Metabolic Solutions Development Company LLC, H1 2017

Parkinson’s Disease – Pipeline by Minerva Neurosciences Inc, H1 2017

Parkinson’s Disease – Pipeline by Mission Therapeutics Ltd, H1 2017

Parkinson’s Disease – Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Montisera Ltd, H1 2017

Parkinson’s Disease – Pipeline by Motac Neuroscience Ltd, H1 2017

Parkinson’s Disease – Pipeline by Neonc Technologies Inc, H1 2017

Parkinson’s Disease – Pipeline by Netherlands Translational Research Center BV, H1 2017

Parkinson’s Disease – Pipeline by Neuralstem Inc, H1 2017

Parkinson’s Disease – Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Neuren Pharmaceuticals Ltd, H1 2017

Parkinson’s Disease – Pipeline by NeuroDerm Ltd, H1 2017

Parkinson’s Disease – Pipeline by NeuroNascent Inc, H1 2017

Parkinson’s Disease – Pipeline by NeurOp Inc, H1 2017

Parkinson’s Disease – Pipeline by Neuropore Therapies Inc, H1 2017

Parkinson’s Disease – Pipeline by New World Laboratories Inc, H1 2017

Parkinson’s Disease – Pipeline by Newron Pharmaceuticals SpA, H1 2017

Parkinson’s Disease – Pipeline by nLife Therapeutics SL, H1 2017

Parkinson’s Disease – Pipeline by Novartis AG, H1 2017

Parkinson’s Disease – Pipeline by Novo Nordisk A/S, H1 2017

Parkinson’s Disease – Pipeline by NsGene A/S (Inactive), H1 2017

Parkinson’s Disease – Pipeline by Omeros Corp, H1 2017

Parkinson’s Disease – Pipeline by Oncodesign SA, H1 2017

Parkinson’s Disease – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by OPKO Health Inc, H1 2017

Parkinson’s Disease – Pipeline by Origenis GmbH, H1 2017

Parkinson’s Disease – Pipeline by Orion Oyj, H1 2017

Parkinson’s Disease – Pipeline by Oryzon Genomics SA, H1 2017

Parkinson’s Disease – Pipeline by Oxford BioMedica Plc, H1 2017

Parkinson’s Disease – Pipeline by ParkCell AB, H1 2017

Parkinson’s Disease – Pipeline by Parkure Ltd, H1 2017

Parkinson’s Disease – Pipeline by Peptron Inc, H1 2017

Parkinson’s Disease – Pipeline by Pfizer Inc, H1 2017

Parkinson’s Disease – Pipeline by Pharma Two B Ltd, H1 2017

Parkinson’s Disease – Pipeline by Pharmaxis Ltd, H1 2017

Parkinson’s Disease – Pipeline by Pharmicell Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Pharnext SA, H1 2017

Parkinson’s Disease – Pipeline by Phenomenome Discoveries Inc, H1 2017

Parkinson’s Disease – Pipeline by Plex Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Prana Biotechnology Ltd, H1 2017

Parkinson’s Disease – Pipeline by Prexton Therapeutics SA, H1 2017

Parkinson’s Disease – Pipeline by Promentis Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Promius Pharma LLC, H1 2017

Parkinson’s Disease – Pipeline by Proteostasis Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Prothena Corp Plc, H1 2017

Parkinson’s Disease – Pipeline by reMYND NV, H1 2017

Parkinson’s Disease – Pipeline by Sage Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by SanBio Inc, H1 2017

Parkinson’s Disease – Pipeline by Saneron CCEL Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Saniona AB, H1 2017

Parkinson’s Disease – Pipeline by Serina Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Shire Plc, H1 2017

Parkinson’s Disease – Pipeline by Sigma-Tau SpA, H1 2017

Parkinson’s Disease – Pipeline by SignPath Pharma Inc, H1 2017

Parkinson’s Disease – Pipeline by Signum Biosciences Inc, H1 2017

Parkinson’s Disease – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by STATegics Inc, H1 2017

Parkinson’s Disease – Pipeline by Stealth BioTherapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Parkinson’s Disease – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Parkinson’s Disease – Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Synthonics Inc, H1 2017

Parkinson’s Disease – Pipeline by Takara Bio Inc, H1 2017

Parkinson’s Disease – Pipeline by TauRx Therapeutics Ltd, H1 2017

Parkinson’s Disease – Pipeline by TechnoPhage SA, H1 2017

Parkinson’s Disease – Pipeline by Teikoku Pharma USA Inc, H1 2017

Parkinson’s Disease – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Parkinson’s Disease – Pipeline by Titan Pharmaceuticals Inc, H1 2017

Parkinson’s Disease – Pipeline by Trevena Inc, H1 2017

Parkinson’s Disease – Pipeline by UCB SA, H1 2017

Parkinson’s Disease – Pipeline by UniQure NV, H1 2017

Parkinson’s Disease – Pipeline by Varinel Inc, H1 2017

Parkinson’s Disease – Pipeline by VistaGen Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by VivaCell Biotechnology Espana SL, H1 2017

Parkinson’s Disease – Pipeline by Voyager Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by vTv Therapeutics Inc, H1 2017

Parkinson’s Disease – Pipeline by Wellstat Therapeutics Corp, H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..1), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..2), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..3), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..4), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..5), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..6), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..7), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..8), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..9), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..10), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..11), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..12), H1 2017

Parkinson’s Disease – Dormant Projects, H1 2017 (Contd..13), H1 2017

Parkinson’s Disease – Discontinued Products, H1 2017

Parkinson’s Disease – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Parkinson’s Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports